ClinicalTrials.gg
CompletedNCT00123253Updated Nov 27, 2013

TH9507 in Patients With HIV-Associated Lipodystrophy

A Phase 3 interventional study of TH9507 in HIV Infections and Lipodystrophy, sponsored by Theratechnologies. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-11-27.

Sponsored by Theratechnologies · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
299th of 2,150
412 · median 60
Started
2005
with 118 others
Phase 3
305 of 2,802
2 open now
Registered
1,435th of 2,802
by date

Among the 2,802 studies in HIV Infections with a site in United States, this one is the 299th largest by enrollment of the 2,150 interventional ones that give a count, is one of 119 that started in 2005, is one of 305 in phase 3, and was the 1,435th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,802 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in association with dyslipidemia and insulin resistance. Data from a previous randomized, placebo-controlled trial demonstrated that daily administration of 2mg TH9507, a growth hormone releasing factor (GRF), to HIV patients with an excess of abdominal fat accumulation for 12 weeks resulted in decreases in visceral adipose tissue (VAT) and trunk fat, with no significant changes in limb fat and subcutaneous adipose tissue (SAT). This study is aimed at further assessing the efficacy and safety of 2 mg TH9507 in a larger population of HIV patients treated with ART and experiencing an excess of abdominal fat accumulation.

03

Conditions studied

  • HIV Infections
  • Lipodystrophy

Keywords

  • HIV
  • Lipodystrophy
  • Abdominal fat accumulation
  • Growth hormone releasing factor/Growth hormone releasing hormone
  • Treatment Experienced
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18 to 65 years inclusive
  • positive; >100 cells/mm3; viral load \<10,000 copies/mL (stable for 8 weeks)
  • On stable ART regimen for at least 8 weeks prior to randomization
  • Have evidence of abdominal fat accumulation defined by the following anthropometric cut off values:

    • For males: waist circumference > 95 cm and waist to hip ratio > 0.94;
    • For females: waist circumference > 94 cm and waist to hip ratio > 0.88.
  • Females of not pregnant or lactating; normal mammography within 6 months of study.
  • Signed

Exclusion criteria

Exclusion Criteria:

  • \< 20 kg/m2
  • Opportunistic infection; -related disease within 3 months of study.
  • History of ; active neoplasm.
  • Prostate-specific antigen (PSA) >5 ng/mL at screening
  • Hypopituitarism; history of pituitary tumor/surgery; head irradiation; head trauma that has affected the somatotropic axis.
  • Untreated hypothyroidism
  • Type 1 diabetics and type 2 diabetics on oral hypoglycemic or insulin sensitizing agent within 6 months of study
  • or AST > 3 x ; serum creatinine > 133 mmol/L (1.5 mg/dL); more than 20 g/L below LLN; fasting blood glucose > 8.33 mmol/L (150 mg/dL); fasting triglycerides > 11.3 mmol/L (0.99 g/dL).
  • Untreated hypertension
  • Change in anti-hyperlipemic regimen within 3 months prior to study
  • Change in testosterone regimen and/or supraphysiological dose of testosterone
  • Estrogen therapy
  • Anoretics/anorexigenics or anti-obesity agents within 3 months of study
  • Growth hormone (GH); GH secretagogues; growth hormone releasing factor (GRF) products; IGF-1; or IGFBP-3 within 6 months of study.
  • Drug or alcohol dependence or use of methadone within 6 months of study entry
  • Participation in a clinical trial with any drug/device within 30 days of screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
412 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Visceral adipose tissue (VAT)

07

Study locations

42 sites
  • UCLA School of Medicine
    Los Angeles, California, United States
  • Office of Dr. Michael Somero
    Palm Springs, California, United States
  • UCSD Medical Center
    San Diego, California, United States
  • Kaiser Permanente
    San Francisco, California, United States
  • AIDS Research Alliance
    West Hollywood, California, United States
  • Capital Medical Associates
    Washington, District of Columbia, United States
  • Bach & Godofsky
    Bradenton, Florida, United States
  • Office of Dr. Gary Richmond
    Ft. Lauderdale, Florida, United States
  • Care Resource Miami
    Miami, Florida, United States
  • Orlando Immunology Center
    Orlando, Florida, United States
  • Infectious Disease Associates
    Sarasota, Florida, United States
  • Treasure Coast Infectious Disease Consultant (TDIDC)
    Vero Beach, Florida, United States
  • AIDS Research Consortium Atlanta (ARCA)
    Atlanta, Georgia, United States
  • Northern Healthcare
    Chicago, Illinois, United States
  • Rush University Medical Center
    Chicago, Illinois, United States
  • Indiana University Department of Medicine
    Indianapolis, Indiana, United States
  • Institute of Human Virology
    Baltimore, Maryland, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland, United States
  • Community Research Initiative of New England
    Boston, Massachusetts, United States
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
  • Tufts University School of Medicine
    Boston, Massachusetts, United States
  • Community Research Initiative of New England (CRI West)
    Springfield, Massachusetts, United States
  • Hennepin County Medical Centre
    Minneapolis, Minnesota, United States
  • AIDS Community Research Initiative of America
    New York, New York, United States
  • Bellevue Hospital Center New York University
    New York, New York, United States
  • St Luke's Roosevelt Hospital Centre
    New York, New York, United States
  • St Vincent Catholic Medical Centre
    New York, New York, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio, United States
  • Fanno Creek Clinic, LLC
    Portland, Oregon, United States
  • Drexel University College of Medicine
    Philadelphia, Pennsylvania, United States
  • Central Texas Clinical Research
    Austin, Texas, United States
  • Dallas VA Medical Centre
    Dallas, Texas, United States
  • The University of Texas Medical School
    Houston, Texas, United States
  • Infectious Disease Physicians Inc.
    Annandale, Virginia, United States
  • Swedish Medical Center
    Seattle, Washington, United States
  • Southern Alberta Clinic
    Calgary, Alberta, Canada
  • St-Paul's Hospital
    Vancouver, British Columbia, Canada
  • Sunnybrook and Women College Health Sciences Centre
    Toronto, Ontario, Canada
  • Windsor Regional Hospital
    Windsor, Ontario, Canada
  • Clinique Médicale du Quartier Latin
    Montreal, Quebec, Canada
  • Clinique Médicale L'Actuel
    Montreal, Quebec, Canada
  • Montreal General Hospital
    Montreal, Quebec, Canada
08

References and documents

Publications

  • Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017 Oct 23;31(16):2253-2259. doi: 10.1097/QAD.0000000000001614. PubMed 28832410 ↗
  • Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10. PubMed 22495074 ↗
  • Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16. PubMed 20554713 ↗
  • Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007 Dec 6;357(23):2359-70. doi: 10.1056/NEJMoa072375. PubMed 18057338 ↗
  • Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff. PubMed 20101189 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Nov 2006 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2005
First posted
Jul 22, 2005
Start
Jun 2005
Primary completionActual
Nov 2006
CompletionActual
Apr 2007
Last update
Nov 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00123253
Lead sponsor
Theratechnologies
First posted
Jul 22, 2005
Start date
Jun 2005
Primary completion
Nov 2006
Completion
Apr 2007
Last update
Nov 27, 2013

Study contacts

Steven Grinspoon, MD
principal investigator · Massachusetts General Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tesamorelin

Start the discussion